Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.57 |
| ▸ | CDK2 | P24941 | 9/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.52 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14492460 | 0.90 | GSK3B (0.52) | GSK3BCDK2CCNE1AHRALDH1A1 | |
| SCHEMBL13998499 | 0.89 | GSK3B (0.71) | GSK3BCDK2CCNE1AHRALDH1A1 | |
| SCHEMBL14492442 | 0.87 | GSK3B (0.57) | GSK3BCDK2CCNE1AHRALDH1A1 | |
| SCHEMBL13998482 | 0.83 | GSK3B (0.68) | GSK3BCDK2CCNE1 | |
| SCHEMBL12953527 | 0.83 | GSK3B (0.81) | GSK3BCDK2CCNE1 | |
| SCHEMBL29644975 | 0.83 | GSK3B (0.81) | GSK3BCDK2CCNE1 | |
| SCHEMBL13998500 | 0.80 | AHR (0.50) | GSK3BCDK2CCNE1AHRALDH1A1 | |
| SCHEMBL13998498 | 0.80 | GSK3B (0.48) | GSK3BCDK2CCNE1AHRALDH1A1 | |
| SCHEMBL12953132 | 0.79 | CDK2 (0.72) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL12953349 | 0.76 | ALDH1A1 (0.50) | GSK3BCDK2CCNE1AHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470695-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470695-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1534709-B1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007044401-A2 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7196092-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196092-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |